Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?

Jeremy W. Jacobs; Laura D. Stephens; David M. Chooljian; Deva Sharma; Brian D. Adkins; Garrett S. Booth

doi:10.1002/ajh.27275

Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?

Jeremy W. Jacobs, Laura D. Stephens, David M. Chooljian, Deva Sharma, Brian D. Adkins, Garrett S. Booth

Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	1016-1018
Number of pages	3
Journal	American Journal of Hematology
Volume	99
Issue number	6
DOIs	https://doi.org/10.1002/ajh.27275
State	Published - Jun 2024

ASJC Scopus Subject Areas

Hematology

Access to Document

10.1002/ajh.27275

OpenUrl availability

Full text

Cite this

@article{8461fa7e9f29481488500c0469fc634f,

title = "Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?",

author = "Jacobs, {Jeremy W.} and Stephens, {Laura D.} and Chooljian, {David M.} and Deva Sharma and Adkins, {Brian D.} and Booth, {Garrett S.}",

year = "2024",

month = jun,

doi = "10.1002/ajh.27275",

language = "English",

volume = "99",

pages = "1016--1018",

journal = "American Journal of Hematology",

issn = "0361-8609",

number = "6",

}

TY - JOUR

T1 - Crizanlizumab and sickle cell disease

T2 - When should medications have their approval status revoked?

AU - Jacobs, Jeremy W.

AU - Stephens, Laura D.

AU - Chooljian, David M.

AU - Sharma, Deva

AU - Adkins, Brian D.

AU - Booth, Garrett S.

PY - 2024/6

Y1 - 2024/6

UR - http://www.scopus.com/inward/record.url?scp=85186586096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85186586096&partnerID=8YFLogxK

U2 - 10.1002/ajh.27275

DO - 10.1002/ajh.27275

M3 - Comment/debate

C2 - 38409818

AN - SCOPUS:85186586096

SN - 0361-8609

VL - 99

SP - 1016

EP - 1018

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 6

ER -

Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?

ASJC Scopus Subject Areas

Access to Document

OpenUrl availability

Other files and links

Cite this